Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?

Affiliations

¹ Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
² Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan.
³ Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
⁴ Department of Hepatobiliary and Pancreatic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
⁵ Department of Medical Oncology, Kyorin University School of Medicine, Tokyo, Japan.
⁶ Department of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, Yokohama City, Kanagawa, Japan.
⁷ Department of Gastroenterology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan.
⁸ Department of Clinical Oncology, St. Marianna University School of Medicine, Kanagawa, Japan.

Comment

Takuji Okusaka et al. Cancer Sci. 2015 Aug.

. 2015 Aug;106(8):1101-2.

doi: 10.1111/cas.12709.

¹ Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
² Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan.
³ Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
⁴ Department of Hepatobiliary and Pancreatic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
⁵ Department of Medical Oncology, Kyorin University School of Medicine, Tokyo, Japan.
⁶ Department of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, Yokohama City, Kanagawa, Japan.
⁷ Department of Gastroenterology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan.
⁸ Department of Clinical Oncology, St. Marianna University School of Medicine, Kanagawa, Japan.

No abstract available

Comment on

Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer.
Okusaka T, Ikeda M, Fukutomi A, Ioka T, Furuse J, Ohkawa S, Isayama H, Boku N. Okusaka T, et al. Cancer Sci. 2014 Oct;105(10):1321-6. doi: 10.1111/cas.12501. Epub 2014 Sep 29. Cancer Sci. 2014. PMID: 25117729 Free PMC article. Clinical Trial.
Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
Sasaki Y, Hamada K, Kaneta T, Takahashi T, Kubota Y, Ishida H, Ichikawa W. Sasaki Y, et al. Cancer Sci. 2015 Aug;106(8):1100. doi: 10.1111/cas.12708. Cancer Sci. 2015. PMID: 26268893 Free PMC article. No abstract available.

1. Okusaka T, Ikeda M, Fukutomi A, et al. Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Cancer Sci. 2014;105:1321–6. - PMC - PubMed
1. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreas cancer. N Engl J Med. 2011;364:1817–25. - PubMed
1. Ychou M, Conroy T, Seitz JF, et al. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol. 2003;14:481–9. - PubMed
1. Conroy T, Paillot B, François E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer–A Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol. 2005;23:1228–36. - PubMed
1. Mahaseth H, Brutcher E, Kauh J, et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas. 2013;42:1311–5. - PubMed